| (Values in U.S. Thousands) | Sep, 2017 | Jun, 2017 | Mar, 2017 | Dec, 2016 | Sep, 2016 |
| Sales | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 |
| Net Income Growth | unch | unch | unch | unch | unch |
Novogen Ltd Ads (NVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NOVOGEN LTD-ADR business is in the area of medicine know as degenerative diseases and disorders. Novogen is addressing this urgent area of medical need through the Novogen isoflavonoid technology platform - a platform that the Company believes offers the real prospect of not only treating, but also preventing, the onset of these common degenerative conditions. There are three divisions at Novagen: the pharmaceutical division, Marshall Edwards inc., and the consumer health division.